FREE Daily Stock Alerts From Stock-PR.com
Power3 Medical Products, Inc. (OTC:PWRM)
PWRM, a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced earlier this month that it delivered four poster presentations at the 2010 International Conference on Alzheimer’s Disease (NASDAQ:ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, PWRM’s diagnostic test, and focused on PWRM’s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.
“In preparation for commercialization, our objective at this meeting was to show how Power3’s protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer’s disease,” said Dr. Ira L. Goldknopf, PWRM’s President and Chief Scientific Officer. “It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3’s protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs.”
“We are pleased that our blood tests specifically diagnose Alzheimer’s in patients, both pre- and post-treatment,” said Helen R. Park, MS, Chief Executive Officer of PWRM, “and that our scientific collaborators, Dr. Marwan Sabbagh, Medical and Scientific Director of the Banner Sun Health Medical Research Institute, and Dr. Lourdes R. Bosquez, President of the Woodlands Behavioral Institute, Inc., presented along with us at the meeting in Hawaii.”
“We are within striking distance of realizing an Alzheimer’s clinical diagnostic tool which I hope will lead to a greater understanding of the disease and buoy the pace of future therapeutic interventions,” added Marwan Sabbagh MD, Medical and Scientific Director of Banner Sun Health Medical Research Institute.
PWRM has filed several patent applications for its NuroPro technology that are currently pending. PWRM also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, PWRM has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. PWRM intends to publish these latest findings as well.
PWRM, a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States. PWRM’s products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease. PWRM’s products analyze proteins and their mutations to assess an individual’s risk for developing disease later in life or a patient’s likelihood of responding to a particular drug; assess a patient’s risk of disease progression and disease recurrence; and measure a patient’s exposure to drug therapy. PWRM was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. PWRM was founded in 1992 and is based in The Woodlands, Texas.
To learn more about PWRM visit: http://www.Power3Medical.com
TriQuint Semiconductor, Inc. (Nasdaq:TQNT)
TQNT hiked its estimates for third-quarter revenue and income, citing strong demand. TQNT expects revenue of $238 million and income excluding items of 27 cents per share for the quarter ended Oct. 2. That compares with TQNT's previous estimates of revenue between $215 million and $225 million and net income of 20 cents per share.
TQNT supplies modules, components, and foundry services to communications companies worldwide. TQNT designs its products on various wafer substrates, such as compound semiconductor materials, including gallium arsenide and piezoelectric crystals. TQNT’s products for the mobile devices market include electronic components for mobile phones, such as transmit modules, power amplifier modules, duplexers, switches, and integrated products.
Entropic Communications, Inc. (Nasdaq:ENTR)
ENTR, a leading provider of silicon and software solutions to enable connected home entertainment, will conduct a conference call with analysts and investors to discuss its third quarter results on Wednesday, October 27, 2010. Entropic will issue a news release announcing the company's third quarter results after the close of the market on October 27, 2010. The text of the press release will also be available on Entropic's web site at www.entropic.com.
ENTR, a fabless semiconductor company, engages in the design, development, and marketing of systems solutions to enable connected home entertainment. ENTR offers home networking chipsets based on the Multimedia over Coax Alliance standard; high-speed broadband access chipsets; integrated circuits that simplify and enhance digital broadcast satellite services; and silicon TV tuner integrated circuits.
Compuware Corporation (Nasdaq:CPWR)
CPWR the technology performance company, announced on Tuesday October 12, 2010 a first-of-its-kind SaaS-based application performance management solution that provides visibility from the First Mile to the Last Mile. The new Gomez First Mile, together with Gomez outside-in monitoring, allows organizations whose business depends on Web applications to quickly assess the business impact of a problem and instantly determine whether the cause of the problem resides in the data center, on the Internet, with a third-party provider or with the user's browser or device.
CPWR provides software and Web performance solutions, professional services, and application services. CPWR's products include File-AID, Xpediter, Hiperstation, Abend-AID, and Strobe products, which are used in application analysis, testing, defect detection and remediation, fault management, file and data management, data compliance, and application service management in the IBM z/OS environment.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).
Sign Up For Free Stock Alerts At http://stock-pr.com/signup
________________________________________Be Sure To Visit stock-pr.ning.com
The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.